BRIEF published on 08/24/2026 at 08:10, 8 days 10 hours ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 8 days 10 hours ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 10 months 1 day ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 10 months 1 day ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 1 year ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
BRIEF published on 07/08/2025 at 08:05, 1 year 1 month ago TME Pharma Terminates Liquidity Contract Amid Cost Optimization Liquidity Contract Biotechnology Refinancing Cost Optimization TME Pharma
PRESS RELEASE published on 07/08/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases TME Pharma terminates liquidity contract with Invest Securities to optimize costs. Improve trading volume of shares and healthy liquidity deemed contract unnecessary. Finds success in refinancing and reducing operational costs Liquidity Contract Cost Optimization Trading Volume Organizational Restructuring TME Pharma
Published on 09/01/2026 at 16:10, 2 hours 25 minutes ago Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development
Published on 09/01/2026 at 15:40, 2 hours 55 minutes ago Norsemont Provides Choquelimpie Drilling Update
Published on 09/01/2026 at 15:30, 3 hours 5 minutes ago Caldwell Launches Global Financial Institutions Group Practice
Published on 09/01/2026 at 14:31, 4 hours 4 minutes ago First Breach Expands Ammunition Manufacturing Capacity with Installation of New Loading and Inspection Equipment
Published on 09/01/2026 at 14:00, 4 hours 35 minutes ago Horizon Aircraft Advances All-Weather Certification Path with the Start of Ice Protection Technology Testing
Published on 09/01/2026 at 18:01, 34 minutes ago Gerresheimer AG: Annual General Meeting Approves the Company's Proposed Resolutions by a Majority Vote
Published on 09/01/2026 at 17:35, 59 minutes ago Aurzen Launches EAZZE E1 and E1R at IFA 2026, Bringing Smart Big-Screen Entertainment to Everyday Spaces
Published on 09/01/2026 at 17:30, 1 hour 5 minutes ago Springer Nature appoints Patric Somlo as Chief Financial Officer
Published on 09/01/2026 at 18:18, 17 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - August 2026
Published on 09/01/2026 at 17:44, 50 minutes ago Reporting on share buyback transactions carried out between August 18 and August 28, 2026
Published on 09/01/2026 at 17:39, 55 minutes ago Disclosure of transactions in own shares of 31 August, 2026
Published on 08/31/2026 at 17:45, 1 day ago Disclosure of transactions in own shares from August 24 to August 28, 2026
